AI tool to predict lymph node spread in high-risk prostate cancer

Trial details

Who runs it

Anhui Medical University

Trial code

NCT07112599

Record updated

9 January 2026

Original description

The pathological-omics and imaging-omics in this study are combined to construct an artificial intelligence (AI) model that can predict whether high-risk prostate cancer patients may have lymph node metastasis. The model determines whether the patient has lymph node metastasis based on the MRI results and the pathological section image information of the case combined with clinical data before radical resection of the prostate. This study is a multicenter, prospective clinical study to verify the model's ability to predict whether high-risk prostate cancer patients may have lymph node metastasis.Read full original descriptionShow less

Clinical Study on Predicting Lymph Node Metastasis of High-risk Prostate Cancer Based on Artificial Intelligence Multi-omics Analysis：A Multicenter, Prospective and Observational Clinical Study

The pathological-omics and imaging-omics in this study are combined to construct an artificial intelligence (AI) model that can predict whether high-risk prostate cancer patients may have lymph node metastasis. The model determines whether the patient has lymph node metastasis based on the MRI results and the pathological section image information of the case combined with clinical data before radical resection of the prostate. This study is a multicenter, prospective clinical study to verify the model's ability to predict whether high-risk prostate cancer patients may have lymph node metastasis.

Inclusion: Age ≥ 50 years; Patients must have histologically or cytologically confirmed prostate adenocarcinoma; PSA ≥ 20ng/ml or Gleason ≥ 8; Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0-2; Life expectancy ≥ 6 months; Normal bone marrow function: absolute neutrophil count ≥ 1.5×109/L; platelets ≥ 75×109/L; hemoglobin ≥ 90g/L; white blood cell count ≥ 3.0×109/L; Normal liver function: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 2.5 times the upper limit of normal (ULN); for patients with liver metastasis, ALT/AST can be ≤ 5 times ULN; Total bilirubin ≤ 1.5 times ULN or total bilirubin > 1.5 times ULN and direct bilirubin ≤ ULN; Normal coagulation function: International Normalized Ratio（INR） ≤ 1.5, partial thromboplastin time (APTT) ≤ 1.5 times ULN, prothrombin time (PT) < ULN + 4 seconds; Normal heart function: left ventricular ejection fraction (LVEF) ≥ 50%; corrected QT interval male < 450ms, female < 470ms, serum potassium ≥ 3.5mmol/L; Normal blood pressure: systolic blood pressure < 140mmHg, diastolic blood pressure < 90mmHg; patients with stable blood pressure assessment after appropriate clinical treatment can be enrolled; Normal renal function: serum creatinine ≤ 1.5 times ULN, and creatinine clearance ≥ 50 mL/min; Prospective subjects can understand and are willing to sign the informed consent form; Able to comply with the study visit schedule and other protocol requirements.

Exclusion: Patients with contraindications to MRI examination, such as metal implants in the body, claustrophobia, etc; Patients with a clear history of neurological and psychiatric disorders, such as dementia, epilepsy, or seizures; In the judgment of the investigator, there are serious concomitant diseases that endanger the safety of the subjects or affect the subjects' completion of this study (such as severe diabetes, thyroid disease, and mental illness, etc.), or factors that affect the safety of the patients or affect the patients' provision of informed consent (including laboratory abnormalities), or any psychological, family, sociological or geographical conditions that affect the study plan and follow-up plan; Patients with any missing baseline clinical and pathological information; The investigator believes that it is not suitable to participate in this clinical trial for any reason; Unable to provide informed consent.

ClinicalTrials.gov NCT07112599